These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 11998550

  • 1. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P.
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [Abstract] [Full Text] [Related]

  • 2. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM, Tanner LA, Milstien JB.
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [Abstract] [Full Text] [Related]

  • 3. Adverse drug event reporting in intensive care units: a survey of current practices.
    Kane-Gill SL, Devlin JW.
    Ann Pharmacother; 2006 Nov; 40(7-8):1267-73. PubMed ID: 16849619
    [Abstract] [Full Text] [Related]

  • 4. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK, Swartz L.
    Arch Intern Med; 2005 Jun 27; 165(12):1363-9. PubMed ID: 15983284
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW.
    Arch Intern Med; 2007 May 28; 167(10):1041-9. PubMed ID: 17533207
    [Abstract] [Full Text] [Related]

  • 6. Provision of information on regulatory authorities' websites.
    Vitry A, Lexchin J, Sasich L, Dupin-Spriet T, Reed T, Bertele V, Garattini S, Toop L, Hurley E.
    Intern Med J; 2008 Jul 28; 38(7):559-67. PubMed ID: 18336542
    [Abstract] [Full Text] [Related]

  • 7. Nurses are increasingly involved in pharmacovigilance in Sweden.
    Ulfvarson J, Mejyr S, Bergman U.
    Pharmacoepidemiol Drug Saf; 2007 May 28; 16(5):532-7. PubMed ID: 17072915
    [Abstract] [Full Text] [Related]

  • 8. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA.
    Med Interface; 1996 May 28; 9(5):85-7. PubMed ID: 10157690
    [Abstract] [Full Text] [Related]

  • 9. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y, Yap CW, Li SC.
    Int J Med Inform; 2008 Jun 28; 77(6):421-30. PubMed ID: 17921048
    [Abstract] [Full Text] [Related]

  • 10. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR, Suh R, Tilson H.
    Pharmacoepidemiol Drug Saf; 2008 Feb 28; 17(2):110-4. PubMed ID: 17724741
    [Abstract] [Full Text] [Related]

  • 11. [Organization and results of drug vigilance in France].
    Bégaud B, Chaslerie A, Haramburu F.
    Rev Epidemiol Sante Publique; 1994 Feb 28; 42(5):416-23. PubMed ID: 7973001
    [Abstract] [Full Text] [Related]

  • 12. Dietary supplement adverse event reports: review and analysis.
    Talati AR, Gurnani AK.
    Food Drug Law J; 2009 Feb 28; 64(3):503-13. PubMed ID: 19999641
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
    Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernández-Benítez M, Fernández LM.
    Ann Pharmacother; 2008 Oct 28; 42(10):1491-6. PubMed ID: 18780808
    [Abstract] [Full Text] [Related]

  • 14. The role of databases in drug postmarketing surveillance.
    Rodriguez EM, Staffa JA, Graham DJ.
    Pharmacoepidemiol Drug Saf; 2001 Oct 28; 10(5):407-10. PubMed ID: 11802586
    [Abstract] [Full Text] [Related]

  • 15. National adverse drug reaction reporting. 1984-1989.
    Faich GA.
    Arch Intern Med; 1991 Aug 28; 151(8):1645-7. PubMed ID: 1872669
    [Abstract] [Full Text] [Related]

  • 16. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S.
    Health Aff (Millwood); 2005 Aug 28; 24(4):938-48. PubMed ID: 16012136
    [Abstract] [Full Text] [Related]

  • 17. Recalls. FDA, industry cooperate to protect consumers.
    Nordenberg T.
    FDA Consum; 1995 Oct 28; 29(8):24-7. PubMed ID: 10151838
    [Abstract] [Full Text] [Related]

  • 18. Adverse drug reactions: a review of relevant factors.
    Ajayi FO, Sun H, Perry J.
    J Clin Pharmacol; 2000 Oct 28; 40(10):1093-101. PubMed ID: 11028248
    [Abstract] [Full Text] [Related]

  • 19. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R.
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005 Oct 28; (123):41-5. PubMed ID: 16541751
    [Abstract] [Full Text] [Related]

  • 20. Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional.
    Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A.
    J Eval Clin Pract; 2004 Nov 28; 10(4):483-9. PubMed ID: 15482410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.